Flynn counsel bemoans CMA treatment
A Flynn Pharma lawyer today argued the UK antitrust enforcer’s phenytoin excessive pricing decision wrongly suggested the company misled the UK’s Department of Health, and did not properly assess evidence of a 2012 meeting between the company and the health ministry.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10